Newly emerged enterovirus-A71 C4 isolates may be more virulent than B5 in northern Vietnam

April 09, 2020

Kanazawa, Japan - Hand-foot-and-mouth disease (HFMD) is an acute viral infection that usually affects infants and children below five years. In a study published in Scientific Reports in January 2020, an international research team including Kanazawa University, the Vietnam National Hospital of Pediatrics, Tokyo Metropolitan Institute of Medical Science, Nagasaki University and Hanoi Medical University, has demonstrated the emergence of a new enterovirus (EV) A71-C4 lineage during the 2015-2016 outbreak of HFMD in northern Vietnam. Further, through clinical studies and an experimental mouse model, they have shown that EV-A71 C4 subgenotype may be more virulent than the B5 subgenotype.

HFMD is a common contagious childhood illness caused by enteroviruses of the family picornaviridae, the most frequently reported being EV-A71, coxsackievirus A16 (CV-A16), and CV-A6. It typically runs a mild self-limiting course; however, in rare cases it may cause inflammation of the meninges and the hindbrain, resulting in paralysis, cardiopulmonary complications, or even death. While most cases resolve within a few weeks, EV-A71 infections may be more severe, with serious complications.

To determine the epidemiological characteristics and identify the various enterovirus strains responsible for HFMD in northern Vietnam, the research team collected and analyzed throat and rectal swabs from 488 affected children in Hanoi.

Son T. Chu, lead author of the study, explains: "CV-A6 was the most common strain, followed by EV-A71. Of these EV-A71, 92.1% were the B5 subgenotype and 7.9% were the C4 subgenotype. Whole-genome sequencing showed that seven of the eight C4a strains formed a new lineage, including two possible recombinants between EV-A71-C4 and CV-A8 strains."

The researchers evaluated the proportion of inpatients as a clinical measure of virulence. Hospitalized children with EV-A71 significantly outnumbered those with CV-A6. Further analysis among the EV-A71 infected children showed that the proportion of inpatients among C4-infected was significantly higher than that among B5-infected, implying greater virulence of C4 than B5.

"As the number of C4-infected patients was small, we applied another technique to compare virulence," says Kyousuke Kobayashi, neurovirologist and lead author. "We inoculated transgenic mice susceptible to EV-A71 infection with viral isolates and monitored them for limb weakness, acute flaccid paralysis, body weight and death. We found increased paralysis and significantly higher mortality among mice infected with C4 strains than those infected with B5 strains."

HFMD is an emerging public health problem with periodic large outbreaks in pediatric populations in East and Southeast Asia. Currently, there is no approved antiviral drug against EV-A71 and the best strategy to mitigate its impact is to develop appropriate vaccines. Though inactivated vaccines exist, more suitable candidate strains may be identified from among the newly emerged EV-A71-C4 strains for developing live attenuated vaccines.
-end-


Kanazawa University

Related Vaccines Articles from Brightsurf:

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M.

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Read More: Vaccines News and Vaccines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.